Morgan Stanley forecasts USD/JPY to fall to 140

Investing.comMonday, November 24, 2025 at 9:24:11 AM
Morgan Stanley forecasts USD/JPY to fall to 140
  • Morgan Stanley has projected that the USD/JPY exchange rate will decline to 140, reflecting ongoing market dynamics and currency fluctuations. This forecast comes amid a backdrop of economic pressures and changing monetary policies in Japan.
  • The anticipated drop in the USD/JPY rate is significant for investors and traders, as it may influence trading strategies and investment decisions in the currency markets. A lower exchange rate could also impact Japan's export competitiveness and economic recovery efforts.
  • This development occurs as the Bank of Japan signals a potential interest rate hike in response to rising inflation and a weakening yen. The interplay between U.S. economic data and Japanese monetary policy is crucial, as it shapes expectations for currency intervention and broader market stability.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended apps based on your readingExplore all apps
Continue Readings
Revolution Medicines stock hits all-time high at 72.76 USD
PositiveFinancial Markets
Revolution Medicines' stock has reached an all-time high of 72.76 USD, reflecting a significant milestone for the company and indicating strong investor confidence in its performance and future prospects.
Morocco stocks higher at close of trade; Moroccan All Shares up 0.73%
PositiveFinancial Markets
Morocco's stock market closed higher, with the Moroccan All Shares index rising by 0.73%. This positive movement reflects a favorable trading environment and investor sentiment in the region.
Relay Therapeutics stock hits 52-week high at $7.65
PositiveFinancial Markets
Relay Therapeutics' stock has reached a 52-week high of $7.65, reflecting a significant increase in investor confidence and market interest in the company's performance. This milestone highlights the positive sentiment surrounding Relay Therapeutics as it continues to develop innovative therapies.
Amneal Pharmaceuticals stock hits 52-week high at $12.12
PositiveFinancial Markets
Amneal Pharmaceuticals' stock has reached a 52-week high of $12.12, reflecting a significant increase in investor confidence and market performance. This milestone indicates a positive trend for the company as it continues to navigate the competitive pharmaceutical landscape.
European Smaller Companies Trust shareholders approve all resolutions
NeutralFinancial Markets
Shareholders of the European Smaller Companies Trust have approved all resolutions presented during the recent meeting, reflecting a consensus on the company's strategic direction and governance. This decision underscores the shareholders' support for the management's proposals and operational plans.
Disc Medicine stock hits 52-week high at 96.09 USD
PositiveFinancial Markets
Disc Medicine's stock has reached a 52-week high of 96.09 USD, reflecting a significant increase in investor confidence and positive market sentiment. This milestone indicates strong performance and potential growth for the company in the current market landscape.
Wizz Air announces leadership changes effective February 2026
NeutralFinancial Markets
Wizz Air has announced leadership changes that will take effect in February 2026, signaling a shift in the company's management structure. This decision was reported by Investing.com on November 24, 2025.
European Commission approves Omnicom's acquisition of IPG
PositiveFinancial Markets
The European Commission has approved Omnicom's acquisition of IPG, marking a significant step in the consolidation of the advertising and marketing sectors. This approval is expected to enhance Omnicom's market position and expand its service offerings.